Research digest — GHRH analogue + selective secretagogue
CJC-1295 Ipamorelin is a research stack pairing a long-acting GHRH analogue with a selective growth-hormone secretagogue.
A broadsheet reading of the published record — what the two arms each established alone, the synergy that justifies pairing them, and the line where the evidence stops.
The short version
CJC-1295 Ipamorelin is a research combination of two lab-made peptides (short protein-like molecules) used to push the body's own growth-hormone system. The first peptide, CJC-1295, is a long-acting copy of a natural signal called GHRH (the hormone that tells the pituitary gland to release growth hormone). The second, ipamorelin, is a "GHRP" — it hits a separate switch, the ghrelin receptor, to fire off a growth-hormone pulse. Pressed together, the two switches add up to a bigger pulse than either alone. Studies of the single ingredients show real, measured rises in growth hormone and IGF-1. But the fixed blend itself has never been put through a controlled human trial, and neither piece is approved as a medicine. What people report — including the downsides, from puffiness to head-rushes — is on the effects page.
What the CJC-1295 Ipamorelin record actually establishes
The combination rests on two independent, well-attributed bodies of work. A single subcutaneous dose of CJC-1295 with DAC raised mean plasma growth hormone (GH) two- to ten-fold for six days or more and IGF-1 (insulin-like growth factor 1, the liver-made messenger that carries out most of GH's effects) 1.5- to three-fold for nine to eleven days in healthy adults; after repeat dosing, IGF-1 stayed above baseline as long as 28 days [1]. Ipamorelin, for its part, is the first selective GH secretagogue: unlike older peptides it released GH without dragging up the stress hormones ACTH or cortisol, even at doses more than 200 times the amount needed for half-maximal GH release [2].
The rationale for pairing them is older than either molecule. In normal men, submaximal doses of a GH-releasing peptide combined with GHRH stimulated GH release synergistically — the two acting through independent mechanisms [3]. That is the load-bearing finding under every "stack" claim: a growth hormone secretagogue and a GHRH analogue together produce more than the sum of their parts.
Cjc ipamorelin: two arms, two timescales
<a id="cjc-ipamorelin"></a>Read honestly, this is not one drug but two, and they run on different clocks. CJC-1295 with DAC carries a Drug Affinity Complex — a chemical hook that covalently bonds to Cys34 of serum albumin, the most abundant protein in blood — which stretches its action to several days [4]. Ipamorelin produces a single short pulse and clears within hours [2]. The "no-DAC" form of CJC-1295, known as Mod GRF (1-29), drops the albumin hook entirely and lasts only about thirty minutes. A reader who treats "the blend" as a single tidy thing is already off the literature: the two halves were studied apart, on timescales that do not match.
The receptor-level mechanism is documented. Co-activating the cloned GHRH and ghrelin receptors in cultured cells produced a cAMP response roughly twice that of GHRH-receptor activation alone, pointing to direct cross-talk between the two pathways [5]. Synergy is real where it has been measured — in cells and in acute human GHRH-plus-GHRP studies — but it has never been measured for this specific fixed pairing.
What the research does not show
No peer-reviewed human pharmacology study has ever tested the pre-mixed CJC-1295 Ipamorelin combination itself. Every combination and efficacy claim is an inference — built from each compound's separate data plus general GHRH+GHRP synergy work that used related peptides, not this exact pair. Neither CJC-1295 nor ipamorelin is approved by the FDA for any human indication; both are sold only as research chemicals. Both are prohibited at all times for athletes under WADA Section S2 (peptide hormones and growth-factor mimetics). The honest framing is that the stack raises GH and IGF-1, with downstream effects on body composition, recovery, and sleep that are studied for the single components or extrapolated from the class — never demonstrated as established human outcomes for the blend. The mechanism is sound; the blend trial does not exist.
How this digest is organized
This site is a published register of the CJC-1295 Ipamorelin literature, kept to the line between studied and extrapolated. The CJC-1295 Ipamorelin research desk walks the mechanism and the key trials; the CJC-1295 Ipamorelin effects page gathers what the research-use community reports alongside cited safety cautions; the dosage desk lays out the doses studied by species and route, with no human protocol; and the CJC-1295 Ipamorelin references page carries every DOI and PubMed identifier behind the claims above. Two dedicated reads go deeper on the cjc 1295 ipamorelin benefits reported in research and on the compound as a growth hormone secretagogue.